#SFHS2608375VNotice Regarding the Decision of the National Union of Health Insurance Funds on Setting the Insured Participation Rate for Pharmaceutical Specialties
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This notice sets the patient cost-sharing rate at 35% for two specific dosages of the pharmaceutical drug YESINTEK, an injectable medication. Patients prescribed this medication and healthcare providers should be aware of this set rate for insurance coverage purposes.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Insured participation rate for YESINTEK set at 35%
- Affects two specific dosages: 45 mg and 90 mg
- Applicable to injectable solutions in prefilled pens
Obligations
What this law requires
Apply a 35% patient cost-sharing rate (taux de participation de l'assuré) for YESINTEK 45 mg (ustekinumab) injectable solution, 0.5 ml (90 mg/ml) in pre-filled pen (CIP code 34009 303 335 1 8)
Apply a 35% patient cost-sharing rate (taux de participation de l'assuré) for YESINTEK 90 mg (ustekinumab) injectable solution, 1 ml (90 mg/ml) in pre-filled pen (CIP code 34009 303 335 2 5)
Ensure prescribed patients are informed of the 35% cost-sharing requirement for YESINTEK 45 mg and 90 mg formulations for insurance coverage calculation purposes